Availability of DOPA in situ and thereafter Dopamine (DA) is the main therapeutic approach to treat the Parkinson's Disease (PD). Human neural stem cells (hNSCs), a good source of DA synthesis and release, have long been demonstrated to be a promising candidate for treating PD. However limited cell sourcing and low-growth rate are major concern of its applicability. Different types of other stem cells or reprogrammed somatic cells, including induced pluripotent stem cells (iPSCs), holds tremendous potentiality for DA synthesis and the treatment of Parkinson's disease (PD). However, several issues like ethical, tumor formation, genetic instability, are undermining their therapeutic application. Further the processes are laborious, time-consuming, and not cost-effective. Here, we compare the potentiality and applicability of using another DOPA-forming, neural crest originated cells, Melanocytes with hNSCs for the possible treatment of PD patients.

No abstract